Is Akebia Therapeutics, Inc. (AKBA) a good stock to buy?

Olyth's institutional analysis of AKBA reveals an Altman Z-Score of -4.77 and a Piotroski F-Score of 3/9. These metrics, combined with its 5-year revenue trend ($0.24B most recent), help investors decide if AKBA fits their risk profile.

What is the current P/E ratio for AKBA?

As of the latest trading session, Akebia Therapeutics, Inc. (AKBA) has a trailing P/E ratio of -68.51.

Who is the CEO of Akebia Therapeutics, Inc.?

The current Chief Executive Officer of Akebia Therapeutics, Inc. is John Butler.

What was AKBA's revenue for the last 5 years?

According to its latest income statements, Akebia Therapeutics, Inc. reported annual revenues of $0.24B (2025), $0.16B (2024), $0.19B (2023), $0.29B (2022), $0.21B (2021) respectively.

Does AKBA pay a dividend?

Akebia Therapeutics, Inc. does not currently pay a dividend to its shareholders.

How much debt and cash flow does AKBA have?

In its latest reporting period, Akebia Therapeutics, Inc. generated $0.07B in Free Cash Flow against a total debt load of $0.22B.

What is the Price-to-Book (P/B) ratio of Akebia Therapeutics, Inc.?

The Price-to-Book (P/B) ratio for Akebia Therapeutics, Inc. (AKBA) is currently 11.23.

What is the Price-to-Sales (P/S) ratio of AKBA?

Based on trailing twelve-month data, Akebia Therapeutics, Inc. (AKBA) trades at a Price-to-Sales (P/S) ratio of 1.57.

What is Akebia Therapeutics, Inc.'s Return on Equity (ROE)?

Akebia Therapeutics, Inc. (AKBA) has a Return on Equity (ROE) of -16.70%, representing its profitability relative to shareholder equity.

AKBA

Akebia Therapeutics, Inc. · Healthcare

1.38

4.55%(+0.06)

1.39

0.72%(+0.01)

After Hours

Last Updated: — ET

52W L: $1.1452W H: $4.08

$1.37

CHG+0.13 (+10.44%)

H$1.56

L$1.23

VOL48M

AKBA (1h)

Company Profile

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Sector

Healthcare

Industry

Biotechnology

Employees

181

IPO Date

2014-03-20

Beta

0.37

Websitewww.akebia.com↗

AKBA

Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium

JPMorgan Chase & Co. Has $2.71 Million Holdings in Akebia Therapeutics, Inc. $AKBA

Akebia Therapeutics R&D Day: Vafseo Growth Plan, Praliciguat Phase 2, New Kidney Pipeline Targets

Akebia Therapeutics, Inc. $AKBA Shares Sold by Assenagon Asset Management S.A.

Akebia Therapeutics, Inc. (AKBA) Discusses Pipeline Progress and Strategic Focus on Kidney Disease Treatments at R&D Day Transcript

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)